Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

Go back to Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
(NASDAQ: SYRE) Delayed: 92.95 +1.55 (1.70%)
Previous Close $91.40    52 Week High $ 
Open $92.78    52 Week Low $ 
Day High $95.17    P/E N/A 
Day Low $92.32    EPS $ 
Volume 1,153,073